Skip to main content
main-content
Erschienen in: Endocrine 2/2022

05.07.2022 | Original Article

Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms

verfasst von: Pin Zhang, Zhiwen Xiao, Huaxiang Xu, Xinzhe Zhu, Lei Wang, Dan Huang, Yun Liang, Quanxing Ni, Jie Chen, Xianjun Yu, Guopei Luo

Erschienen in: Endocrine | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Although glucose has a well-recognized protumoral role and the pancreas is a critical organ in adjusting glucose metabolism, the clinical value of hyperglycemia in pancreatic neuroendocrine neoplasms (pNENs) remains largely unidentified.

Methods

A retrospective study including 335 patients with pathologically confirmed pNENs was conducted. A baseline fasting blood glucose concentration ≥5.6 mmol/L was defined as hyperglycemia (otherwise, normal). Survival and regression analyses were performed.

Results

Compared with patients with normal glucose, patients with hyperglycemia (47.8%) had a higher proportion of preexisting diabetes mellitus (DM) (36.9% vs. 4.6%, p < 0.001), lymph node involvement (31.0% vs. 14.6%, p = 0.002), distant metastasis (34.4% vs. 22.9%, p = 0.019), and carbohydrate antigen 19-9 (CA19-9) ≥ 37 U/mL (16.6% vs. 7.2%, p = 0.009). Hyperglycemia was associated with CA19-9 ≥ 37 U/mL (Odds Ratio (OR) = 3.19, 95% CI: 1.11–9.17, p = 0.031), lymph node involvement (OR = 2.32, 95% CI: 1.02–5.28, p = 0.045), nonfunctional tumors (OR = 9.90, 95% CI: 2.11–46.34, p = 0.004), and preexisting diabetes (OR = 18.24, 95% CI: 4.06–81.95, p < 0.001). Hyperglycemia was an independent determinant for overall survival in the multivariate analysis (hazard ratio (HR) = 2.65, 95% CI: 1.31–5.34, p = 0.006).

Conclusion

Hyperglycemia is an independent predictor of overall survival and is associated with preexisting DM or lymphatic metastasis in patients with pNENs. Patients with hyperglycemia and resectable pNENs may benefit from radical resection with dissection of regional lymph nodes.
Literatur
8.
Zurück zum Zitat T. Feola, G. Puliani, F. Sesti, R. Modica, R. Centello, R. Minotta, G. Cannavale, S. Di Meglio, V. Di Vito, R. Lauretta, M. Appetecchia, A. Colao, A. Lenzi, A.M. Isidori, A. Faggiano, E. Giannetta, Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J. Endocrinol. Invest. 45(4), 849–857 (2022). https://​doi.​org/​10.​1007/​s40618-021-01715-0 CrossRefPubMed T. Feola, G. Puliani, F. Sesti, R. Modica, R. Centello, R. Minotta, G. Cannavale, S. Di Meglio, V. Di Vito, R. Lauretta, M. Appetecchia, A. Colao, A. Lenzi, A.M. Isidori, A. Faggiano, E. Giannetta, Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J. Endocrinol. Invest. 45(4), 849–857 (2022). https://​doi.​org/​10.​1007/​s40618-021-01715-0 CrossRefPubMed
12.
Zurück zum Zitat L. de Mestier, A.L. Vedie, M. Faron, J. Cros, V. Rebours, O. Hentic, C. Do Cao, P. Bardet, P. Levy, A. Sauvanet, P. Ruszniewski, P. Hammel, The postoperative occurrence or worsening of diabetes mellitus may increase the risk of recurrence in resected pancreatic neuroendocrine tumors. Neuroendocrinology 110(11–12), 967–976 (2020). https://​doi.​org/​10.​1159/​000505158 CrossRefPubMed L. de Mestier, A.L. Vedie, M. Faron, J. Cros, V. Rebours, O. Hentic, C. Do Cao, P. Bardet, P. Levy, A. Sauvanet, P. Ruszniewski, P. Hammel, The postoperative occurrence or worsening of diabetes mellitus may increase the risk of recurrence in resected pancreatic neuroendocrine tumors. Neuroendocrinology 110(11–12), 967–976 (2020). https://​doi.​org/​10.​1159/​000505158 CrossRefPubMed
14.
Zurück zum Zitat G. Muscogiuri, B. Altieri, M. Albertelli, A. Dotto, R. Modica, L. Barrea, G. Fanciulli, T. Feola, R. Baldelli, R.M. Ruggeri, M. Gallo, V. Guarnotta, P. Malandrino, E. Messina, M.A. Venneri, E. Giannetta, D. Ferone, A. Colao, A. Faggiano; N. group, Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 69(2), 441–450 (2020). https://​doi.​org/​10.​1007/​s12020-020-02331-3 CrossRefPubMed G. Muscogiuri, B. Altieri, M. Albertelli, A. Dotto, R. Modica, L. Barrea, G. Fanciulli, T. Feola, R. Baldelli, R.M. Ruggeri, M. Gallo, V. Guarnotta, P. Malandrino, E. Messina, M.A. Venneri, E. Giannetta, D. Ferone, A. Colao, A. Faggiano; N. group, Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 69(2), 441–450 (2020). https://​doi.​org/​10.​1007/​s12020-020-02331-3 CrossRefPubMed
23.
Zurück zum Zitat X.F. Zhang, F. Xue, D.H. Dong, A.G. Lopez-Aguiar, G. Poultsides, E. Makris, F. Rocha, Z. Kanji, S. Weber, A. Fisher, R. Fields, B.A. Krasnick, K. Idrees, P.M. Smith, C. Cho, M. Beems, Y. Lv, S.K. Maithel, T.M. Pawlik, New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis. Ann. Surg. 274(1), e28–e35 (2021). https://​doi.​org/​10.​1097/​SLA.​0000000000003478​ CrossRefPubMed X.F. Zhang, F. Xue, D.H. Dong, A.G. Lopez-Aguiar, G. Poultsides, E. Makris, F. Rocha, Z. Kanji, S. Weber, A. Fisher, R. Fields, B.A. Krasnick, K. Idrees, P.M. Smith, C. Cho, M. Beems, Y. Lv, S.K. Maithel, T.M. Pawlik, New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis. Ann. Surg. 274(1), e28–e35 (2021). https://​doi.​org/​10.​1097/​SLA.​0000000000003478​ CrossRefPubMed
27.
Zurück zum Zitat L. Chen, Y. Zhang, M. Chen, J. Chen, Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms. Chin. J. Gastrointest. Surg. 20(9), 1002–1008 (2017) L. Chen, Y. Zhang, M. Chen, J. Chen, Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms. Chin. J. Gastrointest. Surg. 20(9), 1002–1008 (2017)
Metadaten
Titel
Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms
verfasst von
Pin Zhang
Zhiwen Xiao
Huaxiang Xu
Xinzhe Zhu
Lei Wang
Dan Huang
Yun Liang
Quanxing Ni
Jie Chen
Xianjun Yu
Guopei Luo
Publikationsdatum
05.07.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03100-0

Weitere Artikel der Ausgabe 2/2022

Endocrine 2/2022 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.